Home

Overview

Prolonged systemic corticosteroid use in moderate-to-severe atopic dermatitis (AD) carries significant clinical risks, making guideline-directed steroid stewardship essential for patient safety. Join us as we translate guidelines into practice, providing evidence-based strategies to transition patients safely to targeted steroid-sparing regimens.

Speakers

April W. Armstrong, MD, MPH

Faculty

Professor and Chief of Dermatology

University of California, Los Angeles

Los Angeles, California

Lawrence F. Eichenfield, MD

Faculty

Distinguished Professor of Dermatology and Pediatrics

Vice Chair, Department of Dermatology

University of California San Diego School of Medicine

Chief, Pediatric and Adolescent Dermatology

Rady Children’s Hospital

San Diego, California

Agenda

American Academy of Dermatology Guidelines on Atopic Dermatitis

Recent Recommendations on Systemic Corticosteroid Use in AD

Barriers to Incorporating Steroid-Sparing Systemic Treatments Into Practice

Program Information

Accreditation Statement

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

[title]For Physicians[/title] [text]Medscape, LLC designates this live activity for a maximum of 0.50 [bold][italic]AMA PRA Category 1 Credit(s)[/italic][super]TM[/super][/bold]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.[/text] [break] [title]For Nurses[/title] [text]Awarded 0.50 contact hour(s) of nursing continuing professional development for RNs and APNs.[/text]

Learning Objectives

[bold]Upon completion of this activity, participants will be able to:[/bold] [list][item]Summarize potential adverse effects associated with prolonged systemic corticosteroid use in AD [item]Construct AD treatment plans that consider consensus recommendations regarding systemic corticosteroids [item]Identify patients with AD who are candidates for steroid-sparing systemic therapy [/list]

Goal Statement

The goal of this activity is for learners to be better able to treat atopic dermatitis (AD) in accordance with evidence-based recommendations and patients’ goals to minimize flares and disease burden.

Target Audience

This educational activity is intended for an audience of dermatologists, allergists and clinical immunologists, primary care physicians, dermatology and allergy nurse practitioners and physician assistants, and nurses in the United States.

Reducing the Use of Systemic Corticosteroids in Atopic Dermatitis